Jefferies downgraded Biogen Inc (NASDAQ:BIIB), citing the company’s tough setup. Leqembi (lecanemab) sales growth remains ...

Jefferies downgraded Biogen (NASDAQ:BIIB) from a Buy to Hold on monday, citing a challenging outlook for 2025. The firm ...

(Reuters) -Biogen expects growth of its keenly watched Alzheimer's disease drug, Leqembi, to see a "linear trend" in the ...

The firm sees a “tough setup” into 2025 for Biogen with modest Leqembi and Skyclarys US. It see a “real need” for more pipeline and “serious” business development to get investors re-engaged in the ...

In a report released today, Michael Yee from Jefferies downgraded Biogen (BIIB – Research Report) to a Hold, with a price target of ...

Eisai and Biogen have officially launched Leqembi (lecanemab) in South Korea, marking a significant step in Alzheimer’s ...

BofA reinstated coverage of Biogen (BIIB) with a Neutral rating and $178 price target Biogen is “a cheaper name,” mostly ...

Eisai (ESALY) and Biogen (BIIB) announced that the Federal ... anti-soluble aggregated amyloid-beta monoclonal antibody “LEQEMBI” for the treatment of early Alzheimer’s disease.

Mexican health authority approves Leqembi for the treatment of early Alzheimer’s disease: Tokyo Friday, December 6, 2024, 14:00 Hrs [IST] Eisai Co., Ltd. and Biogen Inc. announc ...

1,2 Eisai serves as the lead of LEQEMBI development and regulatory submissions globally with both Eisai and Biogen co-commercializing and co-promoting the product and Eisai having final decision ...

Analysts have recently evaluated Biogen and provided 12-month price targets. The average target is $241.79, accompanied by a high estimate of $300.00 and a low estimate of $180.00. Highlighting a 8.24 ...

Dec 3 (Reuters) - Biogen (BIIB.O), opens new tab expects growth of its keenly watched Alzheimer's disease drug, Leqembi, to see a "linear trend" in the United States in the near term, a company ...